MAP Pharmaceuticals Inc (MAPP1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
2400 BAYSHORE PARKWAY, SUITE 200 MOUNTAIN VIEW, CA 94043

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler.

View SEC Filings from MAPP1 instead.

View recent insider trading info

Funds Holding MAPP1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MAPP1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KELLERMAN DONALD J SVP,CLINICAL DEV & MED AFFAIRS

  • Officer
0 2013-03-01 0

WARD SCOTT R

  • Director
0 2013-03-01 0

KELLEY BERNARD J

  • Director
0 2013-03-01 0

MCPHERRON MATTHEW V

  • Director
0 2013-03-01 0

HENWOOD GERALDINE

  • Director
0 2013-03-01 0

NELSON TIMOTHY S PRESIDENT AND CEO

  • Officer
  • Director
0 2013-03-01 0

OSHEA WILLIAM J

  • Director
0 2013-03-01 0

WOLFF HENRY WARD

  • Director
0 2013-03-01 0

FRIEDMAN CHARLENE A SVP, GEN COUNSEL & SEC

  • Officer
0 2013-03-01 0

GIANAKAKOS ANASTASIOS SVP, CHIEF BUSINESS OFFICER

  • Officer
0 2013-03-01 0

CHAI CHRISTOPHER Y SVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2013-03-01 0

ARMER THOMAS A CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
0 2013-03-01 0

BORLAND SCOTT SVP, NEUROLOGY FRANCHISE

  • Officer
0 2013-03-01 0

FREUND JOHN GORDON

  • Director
  • 10% Owner
5,152 2011-05-19 0

GOLDFISCHER CARL

  • Director
0 2010-05-20 0

ELMS STEVE

  • Director
0 2010-05-20 0

SOROS FUND MANAGEMENT LLC

SOROS GEORGE

SOROS ROBERT

SOROS JONATHAN T ALLAN

  • 10% Owner
No longer subject to file 2010-05-11 0

PERSEUSPUR LLC

PEARL FRANK H

  • 10% Owner
No longer subject to file 2010-05-11 0

PERSEUS SOROS BIOPHARMACEUTICAL FUND LP

  • 10% Owner
No longer subject to file 2010-05-11 0

SFM PARTICIPATION LP

SFM AH LLC

  • 10% Owner
No longer subject to file 2010-05-11 0

PERSEUS SOROS PARTNERS LLC

  • 10% Owner
No longer subject to file 2010-05-11 0

PERSEUS BIOTECH FUND PARTNERS LLC

  • 10% Owner
No longer subject to file 2010-05-11 0

BAY CITY CAPITAL FUND IV, L.P.

  • 10% Owner
No longer subject to file 2010-03-09 0

FIRSTMARK CAPITAL, L.L.C.

  • SEE FOOTNOTE 1
No longer subject to file 2009-07-14 0

PEARL FRANK H

  • 10% Owner
0 2009-05-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments